Shares of PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating) were down 1.3% during trading on Monday . The stock traded as low as $2.35 and last traded at $2.36. Approximately 37,915 shares traded hands during trading, an increase of 329% from the average daily volume of 8,831 shares. The stock had previously closed at $2.39.
PharmaCyte Biotech Trading Down 1.3 %
The firm’s 50-day moving average price is $2.39 and its 200 day moving average price is $2.60.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Featured Articles
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook BrightensÂ
- Deep Value High Yield Newell Brands Is Ready To BottomÂ
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
